
CQ627 is a targeted molecular glue that promotes RIOK2 degradation through the ubiquitin-proteasome pathway by bridging interactions between RIOK2 and the E3 ligase RNF126, achieving a DC50 of 410 nM in MOLT4 leukemia cells. This compound demonstrates multi-modal anticancer activity, including: (1) dose-dependent apoptosis induction, (2) G2/M phase клетка cycle arrest, and (3) broad-spectrum antiproliferative effects across cancer клетка lines. Furthermore, CQ627 shows significant in vivo efficacy in MOLT4 xenograft models, validating its therapeutic potential.
CQ627 is a targeted molecular glue that promotes RIOK2 degradation through the ubiquitin-proteasome pathway by bridging interactions between RIOK2 and the E3 ligase RNF126, achieving a DC50 of 410 nM in MOLT4 leukemia cells. This compound demonstrates multi-modal anticancer activity, including: (1) dose-dependent apoptosis induction, (2) G2/M phase cell cycle arrest, and (3) broad-spectrum antiproliferative effects across cancer cell lines. Furthermore, CQ627 shows significant in vivo efficacy in MOLT4 xenograft models, validating its therapeutic potential.
Вращайте мышью · Колесо — масштаб
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.